IgGenix Unclaimed

Claim this company agent Analyze as a competitor Evaluate as a vendor

www.derekcroote.com

IgGenix is a clinical-stage biotech company developing antibody therapies to treat allergies.

IgGenix is a clinical-stage biotechnology company focused on discovering and developing antibody-based therapies to treat allergies. Led by experienced biotech leaders, the company seeks to translate scientific research into transformative treatments that improve the health and well-being of individuals affected by allergic conditions. IgGenix emphasizes scientific rigor, collaboration, and patient impact as it advances its internal programs through clinical development.

IgGenix's mission is to develop transformational antibody therapies that improve the health and quality of life for people living with allergies.

What we offer

IGNX001

Transformative antibody therapeutic for peanut allergy, completed Phase 1 trial.

iggenix.com/pressreleases/iggenix-announces-first-patient-dosed-in-phase-1-clinical-trial-accelerate-peanut-evaluating-ignx001-in-peanut-allergy/

Market segments

Market size by segment

Growth potential (CAGR)

Peanut allergy therapeutics

1.15 Billion USD16.9% CAGR

Therapies specifically designed to prevent or reduce allergic reactions to peanuts, including monoclonal antibodies and targeted immunotherapies aimed at desensitization and protection from anaphylaxis.

Clinical-stage antibody therapeutics

311.2 Billion USD7.5% CAGR

Monoclonal antibody candidates undergoing clinical development for immune-mediated conditions, with emphasis on clinical safety, efficacy, and advancement through Phase 1–3 trials.

Biopharmaceutical partnering and licensing

15 Billion USD9% CAGR

Opportunities for licensing, co-development, and strategic partnerships around clinical-stage biologic assets to accelerate development, manufacturing, and commercialization.

More information about our offering

IGNX001

IGNX001 is IgGenix's internally developed antibody therapeutic for peanut allergy. It is designed to provide a transformative solution for individuals suffering from this condition and completed a Phase 1 clinical trial in November 2025.

Achieved Phase 1 Clinical Trial
Successfully completed initial human trials, demonstrating its potential efficacy and safety for treating peanut allergies.

References

Methodology and sourcing behind the figures shown above.

Peanut allergy therapeutics

Estimate anchored to market-research figures for the peanut-allergy vaccine/therapeutics segment: Coherent Market Insights reports a peanut allergy vaccine market of USD 1.15B in 2026 with a 16.9% CAGR (2026–2033). That vaccine/immunotherapy-focused projection is corroborated by a LinkedIn-sourced market note (~USD 1.2B in 2026; ~15.5% CAGR) and a MeditechInsights statement of ~12% near-term growth for the broader peanut allergy treatment market. SphericalInsights shows the broader allergy therapeutics market at USD 23.1B (2023), indicating peanut-specific therapeutics are a smaller, rapidly growing subsegment driven by immunotherapies and biologics.

Clinical-stage antibody therapeutics

Used published market forecasts for the broader antibody/monoclonal antibody therapeutics market as the addressable market for clinical‑stage antibody candidates. Primary proxy is MarketsandMarkets (USD 311.2B in 2026; 7.5% CAGR). Other sources show a range (Coherent ~USD 331.8B in 2026, BioSpace USD 233.2B in 2024, PrecedenceResearch USD 973.6B in 2024), so a conservative CAGR (7.5%) and the MarketsandMarkets 2026 market size were used as the baseline for clinical‑stage antibody therapeutics’ near‑term market potential.

Biopharmaceutical partnering and licensing

Estimate based on the overall biopharmaceutical market scale and growth (persistence market research), observed annual licensing revenues from academia (NCBI/PMC) and representative deal economics (PharmExec). Using the $515.8B biopharma market (2025) as context and university licensing revenue (~$6B) plus frequent multi‑million upfronts and multi‑hundred‑million-to‑billion milestone structures in industry deals, partnering and licensing of clinical‑stage biologics is estimated as a multi‑billion annual market (approx. 2–3% of total biopharma market). Growth potential is aligned with the broader biopharma CAGR (8–10%), reflecting increasing strategic collaborations and biologics dealmaking.